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PPG neurons of the lower brain stem and their role in brain GLP-1 receptor
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Trapp S, Cork SC. PPG neurons of the lower brain stem and their role in brain
GLP-1 receptor activation. Am J Physiol Regul Integr Comp Physiol 309: R000–
R000, 2015. First published August 19, 2015; doi:10.1152/ajpregu.00333.2015.—
Within the brain, glucagon-like peptide-1 (GLP-1) affects central autonomic
neurons, including those controlling the cardiovascular system, thermogenesis, and
energy balance. Additionally, GLP-1 influences the mesolimbic reward system to
modulate the rewarding properties of palatable food. GLP-1 is produced in the gut
and by hindbrain preproglucagon (PPG) neurons, located mainly in the nucleus
tractus solitarii (NTS) and medullary intermediate reticular formation. Transgenic
mice expressing glucagon promoter-driven yellow fluorescent protein revealed that
PPG neurons not only project to central autonomic control regions and mesolimbic
reward centers, but also strongly innervate spinal autonomic neurons. Therefore,
these brain stem PPG neurons could directly modulate sympathetic outflow through
their spinal inputs to sympathetic preganglionic neurons. Electrical recordings from
PPG neurons in vitro have revealed that they receive synaptic inputs from vagal
afferents entering via the solitary tract. Vagal afferents convey satiation to the brain
from signals like postprandial gastric distention or activation of peripheral GLP-1
receptors. CCK and leptin, short- and long-term satiety peptides, respectively,
increased the electrical activity of PPG neurons, while ghrelin, an orexigenic
peptide, had no effect. These findings indicate that satiation is a main driver of PPG
neuronal activation. They also show that PPG neurons are in a prime position to
respond to both immediate and long-term indicators of energy and feeding status,
enabling regulation of both energy balance and general autonomic homeostasis.
This review discusses the question of whether PPG neurons, rather than gut-derived
GLP-1, are providing the physiological substrate for the effects elicited by central
nervous system GLP-1 receptor activation.
appetite; brain stem; glucagon-like peptide-1; hippocampus; neuroanatomy
FOR TWO DECADES, IT HAS BEEN known that glucagon-like peptide
(GLP-1) reduces food intake by acting within the central
nervous system (95). That first study showed through the use of
the GLP-1 receptor antagonist exendin-9 (Ex9) that endoge-
nous GLP-1 has the ability to suppress food intake and that this
effect is dependent on the feeding state of the animal. While
unequivocally showing that GLP-1 has a physiological role in
brain, the source of centrally acting GLP-1 remains less clear.
Does postprandially released GLP-1 from the enteroendocrine
L-cells reach the central nervous system (CNS) from the
circulation, despite its short half-life in the blood, or does the
small number of preproglucagon (PPG) neurons in the lower
brain stem (37, 58, 65) provide sufficient GLP-1 for the
plethora of brain regions that express its receptor? Although
this question remains largely unanswered, it is clear that central
GLP-1 is integral to many more processes linked to energy
homeostasis than simply food intake. This review provides a
detailed account of the different actions of GLP-1 in the brain,
with a particular emphasis on the potential role of the PPG
neurons in these processes.
In the brain, the highest levels of GLP-1 were found within
the hypothalamus and thalamus, followed by the lower brain
stem (87). This led to the hypothesis that GLP-1 might be
synthesized as a neurotransmitter within the central nervous
system, and subsequent immunohistochemistry has located
GLP-1 immunoreactivity in cell bodies in the lower brain stem
and axon terminals in hypothalamic nuclei (53). The relative
distribution of GLP-1 between the brain stem and hypothala-
mus seems to reflect that GLP-1 synthesis occurs in the cell
body before transport to axon terminals, where it is stored
ready for release (111). GLP-1-producing neurons have been
identified either by GLP-1 immunoreactivity and were, thus,
called GLP-1 neurons, or through the presence of preproglu-
cagon mRNA (which is translated and cleaved to proglucagon,
the peptide precursor for GLP-1) and were named PPG neu-
rons. Consequently, these two cell populations are expected to
be identical, because proglucagon is processed to GLP-1 and
GLP-2 rather than glucagon in the brain (85). For the purpose
of this review, we use the term PPG neurons to refer to the
Address for reprint requests and other correspondence: S. Trapp, Centre for
Cardiovascular and Metabolic Neuroscience, Dept. of Neuroscience, Physiol-
ogy and Pharmacology, Rockefeller Bldg., Rm. 422, Univ. College London,
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GLP-1-producing cells in the brain no matter how they were
identified, and only differentiate if it is of specific significance.
Gut-Derived GLP-1 and the Brain
When assessing the importance of brain-derived GLP-1, the
first question to address is whether peripheral GLP-1 reduces
food intake. There is strong evidence suggesting it does (22,
29, 81, 82, 102, 103), and the weight loss resulting from
bariatric surgery appears to depend on this (62). The greatly
reduced length of the upper intestinal tract in Roux-en-Y
bypass patients means that nutrients reach the L-cells in the
ileum much faster and at higher concentrations leading to
increased GLP-1 release. Additionally, a recent study suggests
that binge-eating episodes may be linked to reduced circulating
GLP-1 levels in bulimia nervosa patients. However, the in-
creased “fullness” experienced by patients with purging disor-
ders appears not to be linked to increased postprandial GLP-1
release (14).
While peripheral GLP-1 undoubtedly reduces food intake
(102), dissecting the pathways involved turns out to be diffi-
cult. The three main possibilities of how peripheral GLP-1
might exert central effects are the following. 1) Circulating
GLP-1 might have unrestricted access across the blood-brain
barrier (BBB) and act directly on brain GLP-1 receptors
(GLP-1R). 2) Circulating GLP-1 might only access areas of the
brain that express an incomplete BBB, and, thus, GLP-1R
expressed in the area postrema (AP) and the subfornical organ
(11, 65) might act as relays to generate an electrical signal in
brain linked to peripheral GLP-1. 3) Peripheral GLP-1 might
bind to GLP-1R on vagal afferent neurons, for example, at the
portal vein, and generate an electrical signal to the brain. Given
that circulating GLP-1 is rapidly degraded by the enzyme
DPP-IV, the prospect of intestinally released GLP-1 reaching
the brain in sufficient concentration to cross the BBB is
questionable. Most rodent studies have used the infusion of
exogenous GLP-1 or GLP-1 analogs to assess GLP-1 effects.
This usually involved supraphysiological concentrations, and,
depending on both the route of administration and the dose
given, pathways that are not relevant under physiological
conditions might have been recruited. Consequently, results
vary substantially between studies and some suggest that
GLP-1 in the circulation can reach any part of the brain,
whereas others claim that GLP-1 is restricted to areas of the
brain with a leaky BBB (44, 72). The latter view was further
substantiated by the finding that lesioning the area postrema
blocked the effect of hepatoportal vein GLP-1 infusion (76).
Additionally, in most rodent studies peripherally administered
GLP-1 retained its satiety effect after vagotomy or vagal
deafferentation (33, 108). One study demonstrated that the
satiety effect of intraperitoneal GLP-1, but not intravenous
GLP-1, depends on an intact vagal nerve (83). In contrast, in
humans, intravenous GLP-1 seems to be dependent on an intact
vagal nerve to reduce food intake (75).
To clarify the importance of vagal afferents compared with
area postrema GLP-1Rs, a recent study addressed the question
of whether a standard meal raises plasma GLP-1 levels suffi-
ciently to have a physiological effect in brain. Their findings
suggest that the permeability of the BBB might be irrelevant
for postprandial release of GLP-1 because rats that consumed
a 3-g meal within 5–6 min, showed significant elevations in
plasma GLP-1 only in the hepatoportal vein and not in the vena
cava (76). This would suggest that under physiological condi-
tions, GLP-1 receptors within the CNS, except those outside
the BBB, are only reached by brain-derived GLP-1, suggesting
a fundamental role for the PPG neurons.
Treatment with GLP-1 Analogs
The considerations for the physiological situation as de-
scribed above are unlikely to apply when considering the
action of systemically administered stable GLP-1 analogs used
clinically in the treatment of Type 2 diabetes mellitus. Given
that GLP-1 analogs are resistant to DPP-IV inactivation, it
seems feasible that they cross the BBB and exert their actions
directly on GLP-1R in the brain. Indeed, both exendin-4 (Ex4)
and liraglutide retained their food intake inhibitory effect after
vagotomy, suggesting that they act directly in the brain (43).
Similarly, another study found no effect of AP lesioning on
food intake reduction by Ex4 (7). A recent elegant study by
Secher et al. (86) has gone some way further to address this
question. First, animals that had undergone either subdiaphrag-
matic vagotomy or lesion of the AP maintained the weight-
limiting effects of intraperitoneal liraglutide to a similar degree
as sham-operated controls, suggesting that these “entry points”
do not significantly contribute to the therapeutic effects of
liraglutide. Furthermore, fluorescently labeled liraglutide (lira-
glutide750) could access multiple sites located behind the BBB,
such as the hypothalamic paraventricular nucleus (PVN) and
the arcuate nucleus (ARC), as well as in all circumventricular
organs. Collectively, the data strongly suggest that liraglutide
has the ability to cross the BBB and interact with CNS GLP-1R
directly. Thus, the use of GLP-1 analogs is likely to mimic the
full activation of both the peripheral (enteroendocrine) and the
central (neuronal) GLP-1 system at the same time. Whether
this also occurs in a physiological situation is currently unclear.
Inputs to PPG Neurons
Given that PPG neurons are the likely physiological source
of GLP-1 to reach brain GLP-1Rs, it is imperative to know
what signals, and particularly satiety signals, activate these
neurons. Interestingly, PPG neurons do not express GLP-1R
but receive direct synaptic input from the vagus nerve (37).
CCK and leptin, short- and long-term satiety peptides, respec-
tively, increased the electrical activity of PPG neurons, while
ghrelin, an orexigenic peptide, and the melanocortin receptor
agonist melanotan II had no effect (36, 37). Leptin receptors
have been localized to PPG neurons (25, 40) and leptin appli-
cation to the lower brain stem causes an increase in PPG
mRNA transcription in mouse (26). Consequently, it seems
likely that leptin signaling is directly responsible for the cor-
relation between PPG mRNA and fat mass. In that respect, it is
surprising that leptin has no direct effect on PPG neurons in rat
(40, 61). However, a synergistic effect on food intake has been
described, and intracerebroventricular Ex9 attenuated the food
intake suppression by hindbrain leptin delivery (109).
Their location, inputs, and projections suggest PPG neurons
are ideally suited to turn a postprandial rise in hepatoportal
GLP-1 into release of GLP-1 within the brain. This idea is
further supported by the observation that gastric distension,
another satiety signal that activates vagal afferent neurons,
elicited elevated c-Fos expression in GLP-1-immunoreactive
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neurons in rat (100). This makes the PPG neurons an important
initial relay that links peripheral satiety signals to the brain
circuits regulating food intake.
However, more controversy arises when considering the
further signaling pathway. Hayes et al. (32) demonstrated that
blockade of hindbrain GLP-1R reduced gastric distension, but
not duodenal nutrient infusion-induced satiety. If it is assumed
that PPG neurons are activated by both of these signals, we
would have to conclude that Hayes’ observations reflect the
existence of distinct subpopulations of PPG neurons that proj-
ect locally (those activated by gastric distension), and those
that project elsewhere (those activated by duodenal nutrient
infusion), with both of these populations being involved in the
regulation of food intake.
In the absence of definitive answers to these questions, this
review focuses on what we do know about the PPG neurons
and the action of GLP-1 specifically within the CNS, and
addresses the following question instead: Could the small
population of PPG neurons located in the lower brain stem
account for all functions ascribed to GLP-1 in the CNS? While
the most prominent function of GLP-1 in the brain is reduction
of food intake (81, 91, 94, 95, 97) and general metabolic
control, the additional effects are wide reaching. Evidence
suggests involvement in energy expenditure by influencing
thermogenesis from brown adipose tissue (9, 60) and blood
glucose control (47, 84). In addition, effects on cardiovascular
control (106), presumably via the modulation of autonomic
outflow, cognitive function (18), as well as a general neuro-
protective effect (18) have been reported. We will consider
these, in turn, and explore how PPG neurons might be in a
position to fulfill these diverse functions (Fig. 1).
PPG Neuron Anatomy: Projection Targets
To date, we have a very good understanding of the anatom-
ical distribution of PPG cell projections throughout the CNS
and some insight into the distribution of GLP-1 receptors
within the brain. This knowledge allows us to assess whether
the PPG cells would be in a position to deliver GLP-1 to the
sites in the CNS where it is expected to exert its specific
actions.
The anatomy of PPG neurons has been studied most exten-
sively in rat and mouse (53, 56–58), but other species, includ-
ing nonhuman primates (98) and a limited study in humans
(110), confirm a conserved pattern of distribution for the cell
bodies in the nucleus of the solitary tract and the intermediate
reticular nucleus of the lower brain stem. In addition, PPG cell
bodies have been located in the olfactory bulb in rat and
mouse, as well as in the piriform cortex and lumbrosacral
spinal cord of mouse (57, 58, 65).
In both rat and mouse, the PPG axons and terminals are
distributed widely throughout the CNS, with major innerva-
tion, signified by varicose axons, not only in the hypothalamic
nuclei involved in feeding, but also in the amygdala, large parts
of the limbic system, and various nuclei involved in autonomic
control (41, 53, 56–58) (Fig. 2). It is assumed that virtually the
entire distribution of PPG axons within the brain originates
from the PPG neurons in nucleus tractus solitarius (NTS) and
intermediate reticular formation (IRT) (Fig. 2). This is based
on the assumption that PPG cells in the olfactory bulb are local
interneurons (65) and the finding that spinal PPG neurons do
not send ascending axons to the brain (57). This leaves only the
possibility that the small number of PPG neurons within the
piriform cortex might contribute to the PPG axons observed
throughout the brain. Studies in which retrograde tracers were
injected into areas with PPG axon terminals demonstrated
labeling of NTS and IRT PPG neurons, with no obvious
topographical mapping that would suggest the existence of
projection-specific subpopulations of PPG neurons in the brain
stem (5, 16, 53, 57, 92, 99). Similarly, spinal PPG projections,
thus far, only characterized in mouse, originate from both NTS
and IRT PPG cells (57). These spinal projections target pre-
dominantly preganglionic sympathetic neurons located in the
central autonomic area (CAA) and the intermediolateral cell
column (IML) from thoracic to lumbar levels (57).
Brain GLP-1 and Food Intake
Action on hypothalamic sites consistently seems to reduce
food intake linked to satiety, whereas action within the
amygdala and brain stem appears to be linked additionally to
the feeling of visceral malaise and its consequential reduction
in food intake (28, 43, 45, 64, 97). Individual studies have
claimed either a role in conditioned taste aversion for the
amygdala (45) and a homeostatic regulation for the brain stem
(32), or vice versa (28, 43, 97). In contrast, GLP-1 in the
ventral tegmental area (VTA) or the nucleus accumbens
(NAc), appears to selectively reduce the appeal of highly
palatable food as reflected in a reduced meal size, rather than
meal frequency (15, 67) or reduced motivation to work for this
Fig. 1. Functions assigned to glucagon-like peptide (GLP-1) receptor activa-
tion in different parts of the central nervous system and how preproglucagon
(PPG) neurons might be linked to these functions. All areas indicated, except
for the hippocampus, receive some level of direct innervation from PPG
neurons. In the absence of innervation, hippocampal GLP-1 receptors might be
accessible to GLP-1 in the cerebrospinal fluid (CSF). However, the physio-
logical relevance of CSF GLP-1 has not been established yet. Should there be
a role for CSF GLP-1, this could also reach other GLP-1Rs throughout the
CNS. ARC, arcuate nucleus; AMG, amygdala; BNST, bed nucleus stria
terminalis; BP, blood pressure; DMH, dorsomedial hypothalamus; DMNX,
dorsal motor nucleus of the vagus; HR, heart rate; NAc, nucleus accumbens;
PPG, preproglucagon; PVN, paraventricular hypothalamic nucleus; VLM,
ventrolateral medulla; VTA, ventral tegmental area.
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food (13) (for review see Ref. 89), although studies without the
choice of highly palatable food also reported a reduction in
food intake upon injection of GLP-1 into NAc (16) or Ex-4 into
the VTA (13). Given that the limbic system is central for the
rewarding properties of behavior, substances, and food (59),
this is hardly surprising. In fact, several studies have concluded
that activation of GLP-1R in the limbic system can attenuate
the reward from the consumption of cocaine (19, 27) or
amphetamines (19, 21), and even lead to reduced consumption
of narcotics, such as alcohol (20, 88). These observations also
go hand in hand with the presence of GLP-1 receptor mRNA
(65) and PPG projections to the VTA, bed nucleus of the stria
terminalis (BNST), amygdala, nucleus accumbens (NAc), and
lateral septum (LS). In mouse, projections to BNST and LS are
substantially more numerous than to VTA and NAc. Whether
this is also the case in rat remains to be determined. The latest
additions to brain regions implicated in the regulation of food
intake by GLP-1 are the parabrachial nucleus and the hip-
pocampus (4, 39, 78). Notably, the hippocampus, the entire
cerebellum, and most of the cortex, with the exception of the
piriform cortex, are devoid of PPG axons (58). Except for these
small regional discrepancies, there is a good correlation
throughout the brain between the presence of fibers from PPG
neurons and GLP-1 receptors, or GLP-1 action.
Medullary Projections of PPG Neurons
A detailed investigation of the neurochemical identity of the
projection targets of PPG neurons within the brain stem re-
vealed strong projections to catecholaminergic neurons in the
ventrolateral medulla (56). This region of the brain stem and
particularly adrenergic/noradrenergic cells in this area have
been shown to be critically involved in central respiratory and
cardiovascular control (2, 63). This innervation could, thus,
contribute to the effects of central GLP-1 on blood pressure,
heart rate, and more general sympathetic activity (10, 34, 106).
Additionally, a recent study in rat has demonstrated that
activation of GLP-1R in the NTS can reduce hedonic food
intake. Activation of NTS GLP-1R through microinjection of
the GLP-1R agonist Ex4 eliminated the preference for peanut
butter over chow. NTS Ex4 increased dopamine--hydroxy-
lase expression in the NTS, as well as tyrosine-hydroxylase
and dopamine receptor 2 expression in the VTA, suggesting
that GLP-1 acts on NTS catecholaminergic neurons to elicit
this effect (77). Interestingly, these catecholaminergic A2 cells
in the NTS are also activated by food intake, and in contrast to
PPG neurons, which are only activated by satiating meals, A2
neurons are also activated by smaller amounts of food intake
(50), suggesting that this activation is independent of GLP-1
released from PPG neurons.
A somewhat smaller percentage of catecholaminergic neu-
rons in the NTS also received close appositions from PPG
neurons, whereas catecholaminergic neurons in the area pos-
trema (AP) had very sparse innervation from PPG neurons
(56). These catecholaminergic AP cells have been shown to
express GLP-1 receptors (11, 105), and this finding would
suggest that the majority of AP GLP-1 receptors are, indeed,
geared toward sampling blood GLP-1 (72), or ventricular
GLP-1 (39), rather than receiving synaptic inputs from PPG
neurons.
Of the cholinergic cell populations found in the brain stem,
only the dorsal vagal neurons received a significant level of
close appositions from PPG axons. This mirrors functional
studies from rat, which demonstrated that about 50% of pan-
creas-projecting dorsal vagal neurons respond electrically to
GLP-1 in vitro (101) and that Ex4 injection into the dorsal
vagal complex reduces gut motility in vivo (38). Thus, PPG
axons innervating dorsal vagal neurons would be in a prime
position to affect both gut function and, thus, potentially
indirectly appetite, and pancreatic endocrine secretions and,
thereby, blood glucose homeostasis. Additionally, given recent
evidence that 50% of brain stem PPG neurons project directly
to sympathetic preganglionic neurons in the spinal cord (57), it
is also feasible to suggest a direct sympathetic mechanism,
Fig. 2. PPG neuron populations and their main projection targets throughout
the CNS. Schematic indicates the location of the PPG cell bodies (areas in
yellow) and the projections originating from these sites. Line thickness gives
an indication of the relative strength of this innervation. PPG neurons in the
GrO are assumed to be local interneurons, and projections from PPG neurons
in the piriform cortex have not been examined to date. Photomicrographs show
the PPG cell bodies in the lower brain stem and the axon terminals in
hypothalamic target areas. AH, anterior hypothalamic area; ARC, arcuate
nucleus; Barr, Barrington’s nucleus; BNST, bed nucleus stria terminalis; CAA,
central autonomic area; CeA, central amygdala; DMH, dorsomedial hypothal-
amus; DMNX, dorsal motor nucleus of the vagus; GrO, granule cell layer of
the olfactory bulb; IML, intermediolateral cell column; IRT, intermediate
reticular nucleus; LC, locus coeruleus; NAc, nucleus accumbens; NTS, nucleus
tractus solitarii; OVLT, organum vasculosum of the lamina terminalis; PAG,
periaqueductal gray; Pir, piriform cortex; PVN, paraventricular hypothalamic
nucleus; PVT, paraventricular thalamic nucleus; RPa, raphe pallidus; Sep,
Septum; VLM, ventrolateral medulla; VMPO, ventromedial posterior nucleus.
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mediated either through inhibition of hepatic glucose produc-
tion or increased absorption into muscle. Furthermore, hind-
brain PPG neurons are also known to send ascending pro-
jections to forebrain areas, for example, the ARC (58),
known to have connections with presympathetic nuclei,
such as the PVN. This provides a further possible indirect
mechanism through which CNS GLP-1 is able to regulate
plasma glucose. Injection of GLP-1 into the arcuate nucleus,
for example, significantly reduced hepatic glucose produc-
tion following insulin infusion (84).
A third population of brain stem neurons that were found to
receive intense innervation from PPG axons were the seroto-
nergic neurons in the raphe pallidus and the parapyramidal
area, with numerous PPG axon varicosities making contact
with individual 5-HT immunoreactive neurons (56). Like PPG
neurons, serotonin neurons have been shown to be involved in
the regulation of food intake (30, 51), and both cell populations
are activated by visceral malaise (48, 52, 80). Similarly, both
cell populations have been implicated in thermoregulation (34,
70). A hint that GLP-1 and 5-HT pathways might converge
stems from the observation that mice lacking 5-HT2C recep-
tors fail to exhibit satiation upon peripheral administration of
GLP-1 (6). This suggests that 5-HT might be required down-
stream of GLP-1 for satiation. If the 5-HT that would normally
bind to these 5-HT2C receptors were released from the 5-HT
neurons in the raphe pallidus and parapyramidal area, then
GLP-1 receptors on these neurons could be the ones targeted in
chronically decerebrate rats to cause hypothermia and hypo-
phagia (34).
Both the catecholaminergic cells in the ventrolateral medulla
and the serotonergic raphe neurons that receive innervation
from PPG neurons are potentially presympathetic neurons,
which might project directly to preganglionic sympathetic
neurons located in the IML and the CAA of the spinal cord,
and would, thus, constitute another feasible pathway for PPG
neurons to modulate sympathetic outflow. This would also
constitute the “normal” pathway for NTS neurons to exert
sympathetic effects. However, recently it was discovered in
mouse that PPG neurons also send direct projections down into
the spinal cord. In fact 50% of brain stem PPG neurons
appear to do so (57). These direct spinal projections target
primarily preganglionic sympathetic neurons in the IML and
CAA, but also, to a lesser degree, parasympathetic pregangli-
onics in the lumbar cord and relatively small numbers of motor
neurons. This innervation provides a previously unknown path-
way for PPG neurons to directly modulate sympathetic outflow
and, thereby, processes such as heart rate, blood pressure, and
thermoregulation by brown adipose tissue.
Forebrain Projections of PPG Neurons
Detailed knowledge of the specific cell types receiving close
appositions from PPG neurons is more sparse beyond the brain
stem. Electrophysiological data from the VTA and the NAc
suggests that dopaminergic neurons in these regions do not
receive direct close appositions, but that glutamatergic input to
these neurons is modulated by GLP-1 (66, 67). In the parabra-
chial nucleus of mouse, close appositions of PPG axons on
calcitonin gene-related peptide neurons have been reported
(78). Within the PVN, a study in rat characterized cell types
receiving innervation from PPG fibers. These included oxyto-
cin and corticotropin-releasing hormone-producing cells, as
well as primarily the parvocellular subset of vasopressin neu-
rons (92).
If GLP-1 receptors in the brain are activated by brain-
derived GLP-1, it would be expected that the projection pattern
would be mirrored by the expression pattern for GLP-1R. The
distribution of GLP-1 receptors in the brain has been analyzed
in detail by in situ hybridization in the rat (65) and using a
genetic tag in mouse (11). Recently, two mouse lines have been
developed that express Cre-recombinase in GLP-1R-express-
ing cells, or a FLAG-tagged humanized GLP-1 receptor, re-
spectively (42, 79). The distribution of PPG projections in
mouse (56–58) shows a high degree of overlap with the
expression of GLP-1R in both mouse and rat (11, 65). How-
ever, notable differences also exist. For example, GLP-1R is
highly expressed in the CA3 region of the caudal hippocampus
(11, 65), a region devoid of PPG innervation and GLP-1
immunoreactivity (41, 58). This raises two possible scenarios:
1) GLP-1R expressed in these regions act in a presynaptic
manner, i.e., they are located on terminals, which are poten-
tially in distal sites where PPG axons occur; or 2) GLP-1R in
these regions receive GLP-1 from nonneuronal sources.
Hippocampus
This discrepancy raises the question of whether hippocampal
neurons, indeed, express GLP-1 receptors, and if so, what is the
source of the GLP-1 that the hippocampus detects. In the
absence of reliable antibodies to detect GLP-1R (17), the
answer was sought primarily by producing functional data
from the hippocampus. For instance, the observation that
GLP-1 elicits increases in firing rate in dissociated hippocam-
pal neurons (71) led to the speculation that hippocampal GLP-1
may be involved in learning, memory, and even neuroprotec-
tion.
Mice deficient for the GLP-1R gene (Glp1r/) showed an
impaired ability to perform learning and memory tasks (1, 18),
whereas overexpression of the GLP-1R in the hippocampus
improved learning and memory (18). Furthermore, GLP-1 has
been shown to elicit neuroprotective effects within the hip-
pocampus. Pretreatment with GLP-1 in dissociated hippocam-
pal neurons has been shown to be protective against glutamate-
induced excitotoxicity, and oxidative stress-induced apoptosis
(24, 107). This has led to a volume of work examining the
potential for GLP-1-based therapeutics for the treatment of
cognitive impairment and neurodegenerative diseases, such as
Alzheimer’s and Parkinson’s disease (1, 3, 23, 55, 104).
In a mouse model of Alzheimer’s disease, administration of
the GLP-1 analog liraglutide significantly improved memory
retention compared with vehicle-dosed controls (31). Further-
more, chronic administration of liraglutide in these mice re-
sulted in significantly higher numbers of CA1 neurons com-
pared with both wild-type and vehicle controls, suggesting
liraglutide may confer proliferative capabilities in these neu-
rons (31).
Obesity and Type 2 diabetes have long been known to
contribute to cognitive decline (12, 104). Type 2 diabetes has
been associated with an increase in the levels of Alzheimer’s
disease-associated hyperphosphorylated tau in the hippocam-
pus (104). In a rat model of Type 2 diabetes, systemic admin-
istration of the GLP-1 analog Ex4 significantly reduced the
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levels of hyperphosphorylated tau, compared with saline-
treated controls (104). Furthermore, mice on a high-fat diet
showed impaired cognitive scores, which was significantly
improved during treatment with the GLP-1 analog lixisenatide
(54). The mechanisms governing these pathologies are unclear;
however, for obesity-induced cognitive decline, glycemic sta-
tus appears to contribute (69). What remains to be clarified is
whether the improvement in cognition and hyperphosphory-
lated tau levels is due to direct GLP-1 actions within the
hippocampus, or indirectly through improved glycemic con-
trol.
The question of whether GLP-1 can exert direct actions
within the hippocampus was addressed recently. Electrophys-
iological recordings in acute slices from rat hippocampus
demonstrated that application of GLP-1 and Ex4 increased the
amplitude and frequency of postsynaptic inhibitory currents in
hippocampal CA3 pyramidal neurons (49). Additionally, a new
transgenic mouse model expressing Cre-recombinase under the
promoter for GLP-1R (79) demonstrated that GLP-1Rs are
functional in a subset of hippocampal pyramidal cells (11), in
support of the in situ hybridization data from the rat (65) and
nonhuman primate (35).
In the absence of PPG fibers entering the hippocampus, this
leaves open the question as to what is the source of GLP-1 to
reach hippocampal GLP-1Rs under physiological conditions?
Kanoski and colleagues (39) have proposed that PPG neurons
might release GLP-1 into the cerebroventricular space and that
hippocampal neurons might respond to GLP-1 in the cerebro-
spinal fluid. While these authors were able to detect GLP-1 in
the cerebrospinal fluid, the question of the source of this GLP-1
remains open and raises speculations over the mode of GLP-1
release from PPG neurons.
PPG Neurotransmitter
The studies described above have demonstrated close appo-
sitions of PPG varicosities and terminals on other neurons,
indicative of synaptic connections. However, while this pro-
vides a good indication as to whether cells receive inputs from
PPG neurons, it cannot be taken for granted that this input is
the synaptic release of GLP-1 onto those cells. It has recently
been demonstrated in the rat that PPG neurons exhibit immu-
noreactivity for both GLP-1 and the vesicular glutamate trans-
porter vGlut2 in their axon varicosities in the PVN and dorso-
medial hypothalamic nuclei, suggesting that glutamate is a
cotransmitter at synapses within the hypothalamus (111). Sim-
ilarly, we have analyzed PPG axon varicosities in the spinal
cord of mice expressing yellow fluorescent protein (YFP) in
PPG neurons (PPG-YFP mice) and also detected the vesicular
glutamate transporter vGlut2 inside these varicosities (Fig. 3),
confirming the similarity between rat and mouse. These find-
ings suggest that PPG neurons would primarily release gluta-
mate, and the observed expression pattern for their axon and
their innervation of specific cell types might be most relevant
for their glutamatergic phenotype.
Neuropeptide release has been studied most extensively in
the neurosecretory neurons of the hypothalamus. Here, neuro-
peptide containing dense core vesicles were rarely found at
presynaptic sites but were more often observed throughout the
axon shaft and somatodendritic complex (68). Furthermore,
stimulation of these neurosecretory fibers showed putative
neuropeptide release at nonsynaptic sites, such as cell bodies,
axon shafts, and dendrites, in preference to synaptic complexes
(reviewed in detail in Ref. 96). Once released, neuropeptides
have the ability to diffuse through the interstitial space to
targets distal from its site of release. This so-called “volume
transmission”; whereby signals act through less defined spatio-
temporal constraints, is predicated by the high affinity of
neuropeptides to their receptors (picomolar-nanomolar range)
compared with traditional synaptic receptors [nanomolar-mi-
cromolar range (90)]. So far, little attention has been paid to the
mechanism of GLP-1 release. Electrophysiological studies
have shown that GLP-1R have the affinity to respond to GLP-1
in the picomolar and nanomolar range (11, 49), suggesting they
may respond to low levels of GLP-1 in the interstitial space.
The electron microscopy data provided by Zheng et al. (110,
111) demonstrates clearly that GLP-1 and glutamate are pres-
ent in the same terminals; however, the study offers little
insight into how the GLP-1 might be released. No clear dense
core vesicles were observed in the cells analyzed by electron-
microscopy, and thus, it remains unclear whether GLP-1 ves-
icles are released in a strictly synaptic fashion opposite post-
synaptic densities or whether they might be released in a
paracrine fashion, while only glutamate is released synapti-
cally.
Fig. 3. PPG neurons are glutamatergic. Confocal photomicrographs are shown from spinal cord sections obtained from PPG-YFP mice. A: YFP-immunofluo-
rescence (green) revealing PPG axons in thoracic spinal cord. B: vGLUT2 immunofluorescence (red) revealed the presence of glutamatergic vesicles and, thereby,
a glutamatergic cell phenotype, in the same spinal cord section as A. C: overlay of photomicrographs A and B reveals that vGLUT2 immunoreactivity is present
inside PPG axon varicosities visualized in this section, as evident from colocalization of red and green signal (yellow; arrowheads). This suggests that spinally
projecting mouse PPG neurons are glutamatergic (immunostaining produced by I. J. Llewellyn-Smith). Scale bar: 10 m.
Review
R6 GLUCAGON-LIKE PEPTIDE IN THE BRAIN
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00333.2015 • www.ajpregu.org
C
O
L
O
R
F3
AQ: 4
tapraid4/zh6-areg/zh6-areg/zh601915/zh68833d15z xppws S5 9/15/15 4:45 MS: R-00333-2015 Ini: 10/lak/dlh
PPG Cells Outside the Lower Brain Stem
Both PPG neurons, specifically located in the granule cell
layer (93), and GLP-1Rs, located to various cell populations
(65), have been found within the olfactory bulb. Similarly,
PPG neurons have been identified in the piriform cortex, where
they appear to form a small subset of pyramidal neurons (58).
These findings might indicate a further role for GLP-1 in
olfactory signal processing (73). It is attractive to consider that
GLP-1 could modulate the gain of olfactory pathways and,
thus, the importance assigned to olfactory cues. While in a
hungry state, the smell of foods could be perceived as intense
and enticing, and yet, the same smell when satiated could have
a significantly reduced effect on conscious thought. However,
whether GLP-1 indeed plays any role in olfactory processing is
currently purely speculative.
Most recently a population of PPG neurons has been dis-
covered in the lower lumbar and upper sacral spinal cord (57).
While the function of this population is currently unknown,
20% of these cells received close appositions from PPG axon
varicosities, and about 20% had close appositions from cho-
linergic axons. Around 15% of those cells with close apposi-
tions from cholinergic axons also had close appositions from
PPG axons. These neurons were not ascending to the brain and
did not leave the spinal cord like sympathetic or parasympa-
thetic preganglionic neurons. Given their location within the
spinal cord, it might be likely that they influence lumbar-sacral
parasympathetic outflow, but this requires experimental vali-
dation.
Manipulation of PPG Cells In Vivo
While the data discussed thus far make a compelling argu-
ment for a significant role for PPG neurons in the physiological
activation of GLP-1 receptors in the CNS, the ultimate proof
that this is, indeed, the case is still missing, mainly because of
difficulties in dissecting functional effects mediated by these
neurons from those of systemic or exogenous GLP-1. The way
forward here seems to be the selective manipulation of PPG
neurons in vivo. Barrera et al. (8) led the way by using
lentiviral mediated RNA interference to reduce the transcrip-
tion of PPG in the NTS of rat. By stereotaxic injection of this
virus, they managed to reduce PPG mRNA levels in the NTS
by 50% while leaving PPG mRNA levels in the IRT un-
changed. This treatment reduced the density of GLP-1 immu-
noreactive fibers in the PVN by 30% and caused nocturnal
hyperphagia leading to increased body weight. These results
confirmed that PPG neurons clearly play a physiological role in
the regulation of appetite. On the other hand, these authors
failed to demonstrate any effect of NTS PPG knockdown on
energy expenditure, including locomotor activity. Similarly,
glucose tolerance was not altered independently of body
weight. The latter findings were surprising, given the fact that
GLP-1 injection into the CNS affects energy expenditure and
glucose tolerance (46, 47, 84) and suggest that more research
is needed to clarify whether these findings were a result of
insufficient knockdown or genuinely indicate that PPG neurons
are not involved in these processes. In any case, the above
results from Barrera et al. (8) have confirmed a clear role for
PPG neurons in the regulation of short-term food intake, and
their finding of a correlation between NTS PPG mRNA levels
and fat mass further suggests a role for central GLP-1 in the
long-term control of body weight. This finding ties in with the
observation in mouse that leptin activates these neurons (37).
Perspectives and Significance
At the beginning of this review, the question was posed:
Could the small population of PPG neurons located in the
lower brain stem account for all functions ascribed to GLP-1 in
the CNS? The definitive answer is not there yet, but the
anatomical and functional evidence reviewed here clearly sup-
port the notion that it is likely. What is needed now are more
experiments along the lines started by Barrera et al. (8): studies
that interfere directly with the activity of the PPG neurons in
vivo. In fact, the recent development of a transgenic mouse
strain that expresses Cre recombinase under the control of the
glucagon promoter (74) has now opened the door for further
manipulation of the activity of PPG neurons in vivo, and in
addition to the approach taken by Barrera et al. (8), this mouse
allows the simultaneous modulation of the release of GLP-1
and the cotransmitter glutamate from these cells. Given that
neuropeptides often have a modulatory role rather than acting
as the main transmitter, this approach may finally reveal the
true importance of the PPG neurons in the regulation of energy
balance.
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